Investigational new drugs against glioblastoma

Kamson, David Olayinka; Khela, Harmon; Laterra, John

doi:10.1016/b978-0-12-821567-8.00002-6

Cited by 1 publication

(1 citation statement)

References 346 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common subtype of GBM, known as primary GBM, arises de novo without any preceding low-grade precursor lesion. [27,28] Secondary GBM arises from the transformation of a lower-grade astrocytoma. [29] GBM is characterized by a wide range of genetic and epigenetic alterations that contribute to its aggressive behavior.…”

Section: Pathophysiology Of Glioblastomamentioning

confidence: 99%

Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches

Alorfi,

Ashour,

Alharbi

et al. 2024

Medicine

View full text Add to dashboard Cite

Glioblastoma (GBM) is a highly aggressive primary malignant brain tumor with a dismal prognosis despite current treatment strategies. Inflammation plays an essential role in GBM pathophysiology, contributing to tumor growth, invasion, immunosuppression, and angiogenesis. As a result, pharmacological intervention with anti-inflammatory drugs has been used as a potential approach for the management of GBM. To provide an overview of the current understanding of GBM pathophysiology, potential therapeutic applications of anti-inflammatory drugs in GBM, conventional treatments of glioblastoma and emerging therapeutic approaches currently under investigation. A narrative review was carried out, scanning publications from 2000 to 2023 on PubMed and Google Scholar. The search was not guided by a set research question or a specific search method but rather focused on the area of interest. Conventional treatments such as surgery, radiotherapy, and chemotherapy have shown some benefits, but their effectiveness is limited by various factors such as tumor heterogeneity and resistance.

show abstract

Section: Pathophysiology Of Glioblastomamentioning

confidence: 99%